Showing 9221-9230 of 19239 results for "".
- Advancements in Prostate Cancer Screening: PSA, Risk Models, and Genomic Innovationshttps://reachmd.com/news/advancements-in-prostate-cancer-screening-psa-risk-models-and-genomic-innovations/2485341/Stockholm3, paired with PSA screening, improves detection of clinically significant prostate cancer while reducing overdiagnosis and unnecessary procedures — reframing follow-up decisions after an elevated PSA.
- Molecular Pathways in Adipose Inflammation: New Insights into Cardiometabolic Riskhttps://reachmd.com/news/molecular-pathways-in-adipose-inflammation-new-insights-into-cardiometabolic-risk/2485348/SAMHD1 phosphorylation links adipose mitochondrial DNA accumulation to NLRP3 inflammasome activation, driving adipose inflammation in obesity and potentially contributing to systemic metabolic dysregulation. Phosphorylation of SAMHD1 reduces its nuclease activity in
- Chronic Pancreatic Inflammation and Early Tumorigenesis: Unveiling Mechanisms and Potential Biomarkershttps://reachmd.com/news/chronic-pancreatic-inflammation-and-early-tumorigenesis-unveiling-mechanisms-and-potential-biomarkers/2485350/Chronic pancreatic inflammation drives early PDAC initiation in a mutant Kras mouse model, reframing early-detection priorities.<
- RUS-PAT 3D Imaging: Revolutionizing Surgical and Trauma Assessmentshttps://reachmd.com/news/rus-pat-3d-imaging-revolutionizing-surgical-and-trauma-assessments/2485344/RUS-PAT offers rapid, noninvasive 3D imaging for surgical and trauma assessment by combining volumetric soft-tissue and vascular visualization with bedside spe
- Microbiome-Informed Precision Nutrition: Bridging the Gap in Metabolic Healthhttps://reachmd.com/news/microbiome-informed-precision-nutrition-bridging-the-gap-in-metabolic-health/2485346/Microbiome-informed precision nutrition is moving from concept to clinical application, offering individualized dietary guidance grounded in host–microbe interactions and metabolic-response profiling. Small randomized controlled trials and other controlled studies s
- Innovative Use of Genomics and AI in Respiratory Diagnostics Enhances Stewardshiphttps://reachmd.com/news/innovative-use-of-genomics-and-ai-in-respiratory-diagnostics-enhances-stewardship/2485356/A genomics–AI platform that pairs a host biomarker with a large language model improved pathogen detection in a study; investigators estimated that, if available at admission, it could have reduced inappropriate antibiotic use by more than 80%.
- TYK2 Inhibitor ICP-332 Demonstrates Efficacy, Safety in ADhttps://reachmd.com/news/tyk2-inhibitor-icp-332-demonstrates-efficacy-safety-in-ad/2485331/A novel oral TYK2 inhibitor, ICP-332, demonstrated favorable safety and promising efficacy in a recent phase 2 randomized clinical trial for moderate to severe atopic dermatitis (AD). Researchers for the double-blind, placebo-co
- Exploring Cannabidiol-Ion Channel Interactions as Therapeutic Targets in Hepatocellular Carcinomahttps://reachmd.com/news/exploring-cannabidiol-ion-channel-interactions-as-therapeutic-targets-in-hepatocellular-carcinoma/2485315/Cannabidiol–ion channel interactions offer a mechanistic axis to target hepatocellular carcinoma, presenting both therapeutic opportunity and biomarker potential. Ion channels are central dr
- Pregnancy-Related Hypertension: Unveiling Subgroup Disparities in Asian American and Pacific Islander Populationshttps://reachmd.com/news/pregnancy-related-hypertension-unveiling-subgroup-disparities-in-asian-american-and-pacific-islander-populations/2485316/New evidence shows pregnancy-related hypertension risk varies across Asian American, Native Hawaiian, and Pacific Islander subgroups — findings that support tailoring antenatal surveillance to subgroup-specific risk patterns. The study found pronounced heterogeneity across
- Lung Immune Prognostic Index: A Tool for Stratifying Survival in Stage III NSCLChttps://reachmd.com/news/lung-immune-prognostic-index-a-tool-for-stratifying-survival-in-stage-iii-nsclc/2485300/Lung Immune Prognostic Index (LIPI) measured at diagnosis stratifies prognosis in stage III non‑small cell lung cancer, identifying a clear gradient of event‑free and over